News

Monash IVF Group and RHS Joint Media Release

Jun 29, 2017 -

Highlights

  • Following performance validation, Repromed are using DOPlify™ for non-invasive PGS in a clinical trial

  • Potential revolutionary change to the IVF industry

RHS Limited (ASX: RHS) (“RHS”) and Monash IVF Group (“MVF”) are partnering to develop an accurate way to test for chromosome number in embryos without biopsy. Preimplantation Genetic Screening or PGS is usually performed on a small number of cells taken from the developing embryo. The embryo releases DNA from their chromosomes into the culture media that the embryo is growing in, so rather than biopsying the embryo, the approach uses this free DNA in the culture media. The companies are now conducting a prospective pilot clinical trial of non-invasive Preimplantation Genetic Screening (PGS) using this embryo culture media. RHS Managing Director Dr Michelle Fraser said “success in the clinical trial has the potential to change global practice”.

 

Read full media release

< Back to all news